29th Mar 2022 19:28
(Alliance News) Genflow Biosciences PLC - London-based biotechnology firm focused on longevity and development of therapies to counteract the effects of ageing - Begins scientific research collaboration with the University of Rochester's Aging Research Center. Says collaboration will initially research the potential of Sirtuin-6 in reversing the aging process in liver tissue. This is the first step towards a true rejuvenation gene therapy across a range of tissues, it adds.
"We now have the opportunity to demonstrate that SIRT6 can go beyond halting or stopping the aging process but can also reverse it. In effect, we seek to demonstrate that you can take an old liver and make it young again - this is the essence of the epigenetic tissue rejuvenation we are exploring, and it has the potential to be the basis of a revolutionary gene therapy," says Chief Executive Officer Eric Leire.
Current stock price: 9.75 pence, up 22% from January IPO price
By Arvind Bhunjun; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Genflow Biosci